Eric Souied Joins SeaBeLife
French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee
SeaBeLife has appointed Professor Eric Souied, an expert in age-related macular degeneration (AMD), to its scientific committee to enhance its dual-pathway strategy targeting retinal degeneration. As head of ophthalmology at Créteil and Henri Mondor Hospital, Souied will guide the company's ophthalmology program, which inhibits necroptosis and ferroptosis, both significant in retinal diseases. His extensive expertise will inform clinical strategies and trial design for SeaBeLife’s lead candidate, SBL03, aimed at combating geographic atrophy, a severe form of AMD affecting millions globally.
1. SeaBeLife has appointed Professor Eric Souied to its scientific committee.2. Focus on age-related macular degeneration (AMD) and retinal diseases.3. Souied will guide programs targeting necroptosis and ferroptosis.4. He has published over 650 scientific works.5. SBL03 is the lead candidate against geographic atrophy.6. AMD affects 8 million currently; expected to reach 10 million by 2040.7. The company aims to address the underlying causes of degeneration.
